Corona Remedies Ltd. Commences Additional Commercial Production, Boosting Capacity by 240 Million

Corona Remedies Ltd. has announced the commencement of additional commercial production of tablets and capsules at its Bhayla manufacturing facility. The new production line will add 240 million to the facility's available capacity, which currently stands at 600 million out of an installed capacity of 852.80 million. The company's actual production as of March 31, 2025, was 561.49 million, equivalent to a capacity utilization of 93.58%. The new capacity is entirely funded through internal accruals, marking a strategic expansion to meet upcoming market demands, enhance in-house production capabilities, and improve supply chain agility.